Acalabrutinib NEW
Price | $39 | $55 | $75 |
Package | 5mg | 10mg | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-18 |
Product Details
Product Name: Acalabrutinib | CAS No.: 1420477-60-6 |
Purity: 99.95% | Supply Ability: 10g |
Release date: 2024/11/18 |
Product Introduction
Bioactivity
Name | Acalabrutinib |
Description | Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. |
In vitro | When administered orally to mice, ACP-196 demonstrably inhibits the expression of CD86 in CD19+ spleen cells induced by anti-IgM in a dose-dependent manner, with an ED50 of 0.34 mg/kg. This inhibition exceeded 90% of CD86 expression levels after 3 hours post-treatment. |
In vivo | Acalabrutinib does not inhibit EGFR, ITK, and TEC, and does not affect the phosphorylation of EGFR at the Y1068 and Y1173 sites. It has a higher IC50 value than ibrutinib and shows almost no inhibitory activity on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. In in vitro signal detection in primary human chronic lymphocytic leukemia cells, Acalabrutinib inhibits the tyrosine phosphorylation of downstream targets ERK, IKB, and AKT. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 53 mg/mL (113.9 mM) DMSO : 86 mg/mL (184.7 mM) |
Keywords | on-target | Acalabrutinib | CLL | phosphorylation | orally | chronic | leukemia | Inhibitor | ERK | ACP196 | ACP 196 | AKT | tyrosine | lymphocytic | Btk | inhibit | Cys481 | PLCγ2 | Bruton tyrosine kinase | irreversible | IKB |
Inhibitors Related | (±)-Zanubrutinib | CP-547632 | Ibrutinib | IBT6A | Orelabrutinib |
Related Compound Libraries | 高選擇性抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | EMA 上市藥物庫(kù) | 酪氨酸激酶分子庫(kù) | 激酶抑制劑庫(kù) | 抗癌臨床化合物庫(kù) | FDA 上市藥物庫(kù) | 抗癌上市藥物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-12-12 | |
$0.00/10g |
VIP1Y
|
Cangzhou Kangrui Pharma Tech Co. Ltd.,
|
2024-10-18 | |
$1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-11 | |
$0.00/1Kg/Bag |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2023-11-03 | |
$0.00/1g |
VIP2Y
|
shandong perfect biotechnology co.ltd
|
2023-08-02 | |
$30.00/1kg |
Henan Bao Enluo International TradeCo.,LTD
|
2023-07-31 | ||
$0.00/1KG |
VIP3Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2022-11-07 | |
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
$20.00/1KG |
Longyan Tianhua Biological Technology Co., Ltd
|
2020-10-27 | ||
$1.00/1kg |
Hebei Jimi Trading Co., Ltd.
|
2019-03-28 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY